174 related articles for article (PubMed ID: 12191635)
1. BRCA1 methylation: a significant role in tumour development?
Catteau A; Morris JR
Semin Cancer Biol; 2002 Oct; 12(5):359-371. PubMed ID: 12191635
[TBL] [Abstract][Full Text] [Related]
2. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer.
Bianco T; Chenevix-Trench G; Walsh DC; Cooper JE; Dobrovic A
Carcinogenesis; 2000 Feb; 21(2):147-51. PubMed ID: 10657950
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
[TBL] [Abstract][Full Text] [Related]
6. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Esteller M; Silva JM; Dominguez G; Bonilla F; Matias-Guiu X; Lerma E; Bussaglia E; Prat J; Harkes IC; Repasky EA; Gabrielson E; Schutte M; Baylin SB; Herman JG
J Natl Cancer Inst; 2000 Apr; 92(7):564-9. PubMed ID: 10749912
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.
Dhillon VS; Young AR; Husain SA; Aslam M
Br J Cancer; 2004 Feb; 90(4):874-81. PubMed ID: 14970867
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
Stefansson OA; Villanueva A; Vidal A; Martí L; Esteller M
Epigenetics; 2012 Nov; 7(11):1225-9. PubMed ID: 23069641
[TBL] [Abstract][Full Text] [Related]
9. DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter.
Butcher DT; Mancini-DiNardo DN; Archer TK; Rodenhiser DI
Int J Cancer; 2004 Sep; 111(5):669-78. PubMed ID: 15252835
[TBL] [Abstract][Full Text] [Related]
10. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics.
Catteau A; Harris WH; Xu CF; Solomon E
Oncogene; 1999 Mar; 18(11):1957-65. PubMed ID: 10208417
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Wang YQ; Zhang JR; Li SD; He YY; Yang YX; Liu XL; Wan XP
Cancer Sci; 2010 Jul; 101(7):1618-23. PubMed ID: 20487263
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
Kontorovich T; Cohen Y; Nir U; Friedman E
Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
[TBL] [Abstract][Full Text] [Related]
14. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Hansmann T; Pliushch G; Leubner M; Kroll P; Endt D; Gehrig A; Preisler-Adams S; Wieacker P; Haaf T
Hum Mol Genet; 2012 Nov; 21(21):4669-79. PubMed ID: 22843497
[TBL] [Abstract][Full Text] [Related]
15. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
[TBL] [Abstract][Full Text] [Related]
16. Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM; Spearman AD; Tseng SY; Sweet K; Toland AE
Fam Cancer; 2009; 8(4):339-46. PubMed ID: 19340607
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
18. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
[TBL] [Abstract][Full Text] [Related]
19. Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.
Pang D; Zhao Y; Xue W; Shan M; Chen Y; Zhang Y; Zhang G; Liu F; Li D; Yang Y
Med Oncol; 2012 Sep; 29(3):1561-8. PubMed ID: 22076508
[TBL] [Abstract][Full Text] [Related]
20. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.
Rice JC; Ozcelik H; Maxeiner P; Andrulis I; Futscher BW
Carcinogenesis; 2000 Sep; 21(9):1761-5. PubMed ID: 10964110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
